# Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

> **NCT05372692** · NA · COMPLETED · sponsor: **Weijia Fang, MD** · enrollment: 3 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** mesothelin-specific chimeric antigen receptor T cell injection

## Key facts

- **NCT ID:** NCT05372692
- **Lead sponsor:** Weijia Fang, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-12
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372692, "Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05372692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*